Medical monitoring

Generex Biotechnology Subsidiary NuGenHealth Contracts with Florida Health Care Associates to Provide Remote Patient Monitoring (RPM) Services

Retrieved on: 
Thursday, May 6, 2021
Medicine, Medical specialties, Clinical medicine, Medical monitoring, Communication, Forward-looking statement, Pulse oximetry, Blood glucose monitoring, Monitoring

NuGenHealth will also supply FHCA with Bluetooth connected blood pressure monitors, electronic scales, glucose monitors, and pulse oximeters for their eligible patient population.

Key Points: 
  • NuGenHealth will also supply FHCA with Bluetooth connected blood pressure monitors, electronic scales, glucose monitors, and pulse oximeters for their eligible patient population.
  • Remote patient monitoring is a service that was positioned for significant growth as the pandemic has accelerated the practice of remote patient monitoring to improve outcomes.
  • Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
  • Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.\n'

VitalConnect Wirelessly Monitors COVID-19 Patients at Northwell Plainview Hospital

Retrieved on: 
Wednesday, May 5, 2021
Technology, Medical devices, Infectious diseases, Hospitals, Cardiology, Biotechnology, Hardware, General Health, Health, Data management, Medical specialties, Medicine, Medical monitoring, Health care, Intensive care medicine, Cardiac electrophysiology, Cardiac monitoring, Plainview Hospital, Monitoring, Hospital

VitalConnect has been working with Northwell Health since March of 2020 to monitor COVID-19 patients, integrate with third-party devices and increase patient-monitoring capacity across hospital units at Plainview Hospital.\nAlong with the COVID-19 use case, Northwell is also looking to explore VitalConnect\xe2\x80\x99s wearable, hospital-grade technology for additional deployments such as hospital at home, transitional care and inpatient expansion.\n\xe2\x80\x9cThe Vista Solution real-time monitoring transformed how our clinicians at Plainview Hospital monitor our patients\xe2\x80\x99 vital signs and manage our patient flow.\xe2\x80\x9d said Tom Luzzi, Director of Patient Care.

Key Points: 
  • VitalConnect has been working with Northwell Health since March of 2020 to monitor COVID-19 patients, integrate with third-party devices and increase patient-monitoring capacity across hospital units at Plainview Hospital.\nAlong with the COVID-19 use case, Northwell is also looking to explore VitalConnect\xe2\x80\x99s wearable, hospital-grade technology for additional deployments such as hospital at home, transitional care and inpatient expansion.\n\xe2\x80\x9cThe Vista Solution real-time monitoring transformed how our clinicians at Plainview Hospital monitor our patients\xe2\x80\x99 vital signs and manage our patient flow.\xe2\x80\x9d said Tom Luzzi, Director of Patient Care.
  • The VitalPatch allows real-time remote or in-hospital monitoring, cardiac monitoring and a solution for monitoring patients with COVID-19 allowing physicians to monitor patients without necessarily taking up bed space needed for patients with more immediate needs and limiting exposure for patients and staff.\nVitalConnect is a leader in wearable biosensor technology for wireless patient monitoring in both hospital and remote patient populations.
  • VitalConnect leverages extensive expertise in biomedical engineering, data analytics, chip design, and mobile and cloud software to create technology that supports decision-making paradigms that achieve better health and economic outcomes.
  • VitalConnect\xe2\x80\x99s products are designed for use in a broad range of inpatient and outpatient settings, such as hospital monitoring, post-discharge care, cardiac monitoring and pharmaceutical solutions.

Nemaura Medical to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 14, 2021

Retrieved on: 
Tuesday, May 4, 2021
Medicine, Health, Clinical medicine, Nemaura Medical, Diabetes, Medical monitoring, Blood glucose monitoring, Continuous glucose monitor, Medical device, XC2, Prediabetes

b'Loughborough, England, May 04, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that management will participate at the Benzinga Global Small Cap Conference on May 14, 2021.\nChief Executive Officer Faz Chowdhury, Ph.D. will deliver his corporate presentation at 3:15pm ET on May 14, 2021.\nInvestors can also request a one-on-one meeting with Dr. Chowdhury to be arranged following the conclusion of the conference.\nInvestors can register for the conference here: https://www.benzinga.com/events/small-cap/global/\nNemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices.

Key Points: 
  • b'Loughborough, England, May 04, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that management will participate at the Benzinga Global Small Cap Conference on May 14, 2021.\nChief Executive Officer Faz Chowdhury, Ph.D. will deliver his corporate presentation at 3:15pm ET on May 14, 2021.\nInvestors can also request a one-on-one meeting with Dr. Chowdhury to be arranged following the conclusion of the conference.\nInvestors can register for the conference here: https://www.benzinga.com/events/small-cap/global/\nNemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices.
  • The company is currently commercializing sugarBEAT\xc2\xae and proBEAT\xe2\x84\xa2.
  • sugarBEAT\xc2\xae, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes.
  • Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT\xc2\xae to the U.S. FDA.

DeCurtis Corporation Receives a New US Patent Focused on Contact Tracing via Location Service

Retrieved on: 
Tuesday, May 4, 2021
Articles, Health sciences, Health, Contact tracing, Epidemiology, Medical monitoring, Pandemics, Public health, Invention

The patent, titled "Contact Tracing via Location Service," focuses on an innovative methodology of rapidly capturing and reporting data pertinent to an individual\'s location in an area as well as their proximity to others.

Key Points: 
  • The patent, titled "Contact Tracing via Location Service," focuses on an innovative methodology of rapidly capturing and reporting data pertinent to an individual\'s location in an area as well as their proximity to others.
  • The invention also allows a reliable way to report based on configurable variables such as distance and exposure time.
  • This patent is a vital part of the DeCurtis Experience Platform\'s revolutionary approach to location and proximity solutions.\n"DeCurtis has again inverted the model with this new patented methodology," said Derek Fournier, President and Chief Executive Officer, DeCurtis Corporation.
  • "\nUsing the location technology of the DeCurtis Experience Platform, reports can be generated by an infected individual\'s wearable or other beacon, creating a timeline that shows past locations and other individuals possibly exposed.

Biobeat's AI-Powered Remote Patient Monitoring Platform Receives A Full CE Mark

Retrieved on: 
Tuesday, May 4, 2021
Medical specialties, Human–computer interaction, Distributed computing architecture, Telehealth, Wearable devices, Medical monitoring, Ambient intelligence, Internet of things, Monitoring, Remote patient monitoring, Wearable technology

Additionally, the approval comprises Biobeat\'s wireless capabilities, which include its proprietary Gateway (hospital) connectivity tool, Mobile App (home), and cloud-based web management platform for healthcare providers, which provide healthcare staff with a continuous, scalable view of patient health and predictive patient deterioration alerts.\n"We are proud to receive CE Mark for the full gamut of remote patient monitoring capabilities that our wearable wrist and chest monitors and AI-enabled patient management tools can provide," said Arik Ben Ishay, CEO of Biobeat.

Key Points: 
  • Additionally, the approval comprises Biobeat\'s wireless capabilities, which include its proprietary Gateway (hospital) connectivity tool, Mobile App (home), and cloud-based web management platform for healthcare providers, which provide healthcare staff with a continuous, scalable view of patient health and predictive patient deterioration alerts.\n"We are proud to receive CE Mark for the full gamut of remote patient monitoring capabilities that our wearable wrist and chest monitors and AI-enabled patient management tools can provide," said Arik Ben Ishay, CEO of Biobeat.
  • "With this approval, we further our goal of improving care and elevating patient outcomes across the European healthcare continuum, which now includes the new care frontier: the home.
  • The wireless solutions connect to a cloud-based patient management system to provide medical staff with real-time data and alerts, enabling early identification of clinical deterioration.
  • Biobeat\'s wearable devices are the first devices to be FDA-Cleared for cuffless non-invasive PPG-based blood pressure monitoring and are also CE Mark certified.

Study Investigates the Ability of Masimo PVi® to Predict Preload Responsiveness in Patients On Nasal High-Flow Therapy

Retrieved on: 
Monday, May 3, 2021
General Health, Pharmaceutical, Health, Medical devices, Medicine, Branches of biology, Clinical medicine, Medical monitoring, Cardiovascular physiology, Masimo, Pulse oximetry, XC2, Preload, CO-oximeter

PVi was measured using a Masimo Radical-7\xc2\xae Pulse CO-Oximeter\xc2\xae with a pulse oximetry sensor attached to the finger.

Key Points: 
  • PVi was measured using a Masimo Radical-7\xc2\xae Pulse CO-Oximeter\xc2\xae with a pulse oximetry sensor attached to the finger.
  • Preload responsiveness was defined as a \xe2\x89\xa5 10% increase in SV after PLR.
  • A fluid challenge was then conducted by administering a 250-mL saline solution to patients who were found to be preload responders (12 of the 20 patients).
  • SV/CO and PVi were measured again after the fluid challenge in these patients.\nThe researchers found that preload responders showed higher baseline PVi values and \xce\x94PVi after PLR.

Assure Holdings Enters into In-Network Agreement with Aetna Colorado

Retrieved on: 
Wednesday, April 28, 2021
Clinical medicine, Anesthesia, Electrodiagnosis, Electroencephalography, Intraoperative neurophysiological monitoring, Medical monitoring, XE-class submarine, Branches of biology

b'DENVER, April 28, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the \xe2\x80\x9cCompany\xe2\x80\x9d or \xe2\x80\x9cAssure\xe2\x80\x9d) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (\xe2\x80\x9cIONM\xe2\x80\x9d), is pleased to announce that it has signed an agreement (the \xe2\x80\x9cAgreement\xe2\x80\x9d) with Aetna Colorado (\xe2\x80\x9cAetna\xe2\x80\x9d).

Key Points: 
  • b'DENVER, April 28, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the \xe2\x80\x9cCompany\xe2\x80\x9d or \xe2\x80\x9cAssure\xe2\x80\x9d) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (\xe2\x80\x9cIONM\xe2\x80\x9d), is pleased to announce that it has signed an agreement (the \xe2\x80\x9cAgreement\xe2\x80\x9d) with Aetna Colorado (\xe2\x80\x9cAetna\xe2\x80\x9d).
  • \xe2\x80\x9cExecuting this Agreement is another important step forward as Assure further develops an in-network revenue stream.\xe2\x80\x9d\nFarlinger added, \xe2\x80\x9cThis Agreement reduces Assure\xe2\x80\x99s risk, minimizes complexity and accelerates payment on cases associated with Aetna Colorado.
  • Assure employs its own staff of technologists and uses its own state-of-the-art monitoring equipment, handles 100% of intraoperative neuromonitoring scheduling and setup, and bills for all technical services provided.
  • Assure Neuromonitoring is recognized as providing the highest level of patient care in the industry and has earned the Joint Commission\xe2\x80\x99s Gold Seal of Approval\xc2\xae.

Aloe Care Health Partners With BioIntelliSense To Integrate Groundbreaking Continuous Vital Sign Monitoring For Scalable Remote Patient Care

Retrieved on: 
Wednesday, April 28, 2021
Medical specialties, Medicine, Health, Telehealth, Intensive care medicine, Medical monitoring, Remote patient monitoring, Monitoring, Aloe

Additional details on the technical and product integration will be shared closer to launch.\n"This combination is truly the next generation of remote patient monitoring," said Ray Spoljaric, CEO and co-Founder of Aloe Care Health.

Key Points: 
  • Additional details on the technical and product integration will be shared closer to launch.\n"This combination is truly the next generation of remote patient monitoring," said Ray Spoljaric, CEO and co-Founder of Aloe Care Health.
  • They were an obvious choice to become the first RPM devices certified on the Aloe Care Health platform.
  • The collaboration with Aloe Care extends our reach and simplifies deployments where connectivity exists in the home via the Aloe Care hub.
  • Interested partners should email [email protected] .\nBioIntelliSense is ushering in a new era of continuous health monitoring and clinical intelligence for Remote Patient Monitoring (RPM).

Global $6.60 Billion Pulse Oximeters and Spirometers Market Opportunities and Strategies, 2015-2019, 2023F, 2025F, 2030F

Retrieved on: 
Wednesday, April 28, 2021
Medicine, Clinical medicine, Health care, Cardiology, Medical monitoring, Pulse oximetry, Masimo, Spirometer, Compound annual growth rate

b'DUBLIN, April 28, 2021 /PRNewswire/ -- The "Pulse Oximeters and Spirometers Global Market Opportunities and Strategies to 2030: COVID-19 Implications and Growth" report has been added to ResearchAndMarkets.com\'s offering.\nPulse Oximeters and Spirometers Global Market Opportunities and Strategies to 2030: COVID-19 Implications and Growth provides the strategists, marketers and senior management with the critical information they need to assess the global pulse oximeters and spirometers market.\nThe global pulse oximeters and spirometers market reached a value of nearly $2,603.8 million in 2019, having grown at a compound annual growth rate (CAGR) of 7.5% since 2015, and is expected to grow at a CAGR of 10.9% to nearly $3,939.0 million by 2023.

Key Points: 
  • b'DUBLIN, April 28, 2021 /PRNewswire/ -- The "Pulse Oximeters and Spirometers Global Market Opportunities and Strategies to 2030: COVID-19 Implications and Growth" report has been added to ResearchAndMarkets.com\'s offering.\nPulse Oximeters and Spirometers Global Market Opportunities and Strategies to 2030: COVID-19 Implications and Growth provides the strategists, marketers and senior management with the critical information they need to assess the global pulse oximeters and spirometers market.\nThe global pulse oximeters and spirometers market reached a value of nearly $2,603.8 million in 2019, having grown at a compound annual growth rate (CAGR) of 7.5% since 2015, and is expected to grow at a CAGR of 10.9% to nearly $3,939.0 million by 2023.
  • Low per capita healthcare expenditure, lack of awareness and training, queries regarding the accuracy of readings, and insufficient information about spirology are major factors that could hinder the growth of the pulse oximeters and spirometers market in the future.\nThe pulse oximeters and spirometers market is relatively concentrated.
  • The top ten competitors in the market made up to 40.13% of the total market in 2019.
  • Major players in the market include Masimo Corporation, Medtronic plc, Koninklijke Philips N.V., Halma plc and Vyaire Medical.\n'

ESO Partners with Philips, Integrates Philips Tempus Pro with ESO EHR to Capture Essential On-Scene Clinical Data

Retrieved on: 
Wednesday, April 28, 2021
Cardiac electrophysiology, Cardiac monitoring, Medical monitoring, Neso, Electronic health records, Branches of biology, Health informatics

With this integration, providers can import critical clinical data from Tempus ALS into a patient\'s EHR record for accurate, rapid reporting.\n"Access to timely data can make all the difference when it comes to patient care," said Dr. Brent Myers, Chief Medical Officer for ESO.

Key Points: 
  • With this integration, providers can import critical clinical data from Tempus ALS into a patient\'s EHR record for accurate, rapid reporting.\n"Access to timely data can make all the difference when it comes to patient care," said Dr. Brent Myers, Chief Medical Officer for ESO.
  • "Our partnership with a strong leader like Philips will help accelerate the capture and distribution of critical data during time-sensitive emergencies to ensure EMS providers are making the most informed decisions possible.
  • "\nPhilips Tempus Pro is a rugged, lightweight cardiac monitor that can be carried in one hand.
  • "\nESO (ESO Solutions, Inc.) is dedicated to improving community health and safety through the power of data.